Publications
Detailed Information
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyo-Pyo | - |
dc.contributor.author | Seo, Sang-Soo | - |
dc.contributor.author | Ryu, Sang-Young | - |
dc.contributor.author | Kim, Jong-Hyeok | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Park, Sang-Yoon | - |
dc.contributor.author | Nam, Joo-Hyun | - |
dc.contributor.author | Kang, Soon-Beom | - |
dc.contributor.author | Lee, Kyung-Hee | - |
dc.contributor.author | Song, Yong Sang | - |
dc.date.accessioned | 2010-06-30T07:58:24Z | - |
dc.date.available | 2010-06-30T07:58:24Z | - |
dc.date.issued | 2008-04-15 | - |
dc.identifier.citation | Gynecol Oncol. 2008;109(3):359-363 | en |
dc.identifier.issn | 1095-6859 (Electronic) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18405948 | - |
dc.identifier.uri | http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6WG6-4S80CP0-1-1&_cdi=6814&_user=168665&_orig=search&_coverDate=06%2F30%2F2008&_sk=998909996&view=c&wchp=dGLbVlz-zSkzk&md5=86a2bc37296f11b254d7bbb37aff5312&ie=/sdarticle.pdf | - |
dc.identifier.uri | https://hdl.handle.net/10371/68075 | - |
dc.description.abstract | BACKGROUND: To evaluate the toxicity and efficacy of a newly developed topoisomerase I inhibitor, CKD-602 in second-line therapy of ovarian cancer. METHODS: We enrolled 24 patients with recurrent ovarian cancer, of median age 54 years (range, 39-64). Eleven patients had measurable lesions on CT scan, and the other 13 had increased serum CA-125 levels. Eighteen patients had platinum-sensitive disease (minimum treatment free interval > or =6 months) and 6 had platinum-resistant disease (minimum treatment free interval <6 months). CKD-602 (0.5 mg/m(2)/day) was administered intravenously for 5 days every 3 weeks. The median number of courses per patient was 6 (range, 1 to 12). Response was evaluated by the evaluation of the size of the mass by CT scan and CA-125 response. RESULTS: The overall response rate was 45.0% (9/20), with 4 patients exhibiting partial responses and 5 patients exhibiting 75% CA-125 responses in 20 evaluable patients. Of the 9 responsive patients, 8 were platinum-sensitive (8/15, 53.3%) and 1 was platinum-resistant (1/5, 20.0%). An additional 5 patients showed stable disease, whereas 6 patients exhibited progressive lesions. Of 24 patients, the most common toxicity was hematological, with grades 3 or 4 neutropenia developing in all 24 patients (100%) and in 94 cycles (71.7%). Grade 3 thrombocytopenia developed in 4 patients (16.7%) and 6 cycles (4.6%). None of the patients experienced grades 3 and 4 gastrointestinal toxicities, including nausea, vomiting, and anorexia. CONCLUSIONS: The newly developed topoisomerase I inhibitor, CKD-602, showed activity against both platinum-sensitive and -resistant ovarian cancer, with acceptable toxicity. | en |
dc.description.sponsorship | This study was supported by a grant of the Korea Health 21
R&D Project, Ministry of Health & Welfare, Republic of Korea (A010194). We thank Chong Kun Dang Pharm. for providing CKD-602 and Soon-Kil Ahn, Hong-Woo Lee and Nam-Song Choi for the excellent support. | en |
dc.language.iso | en | - |
dc.publisher | Elsevier | en |
dc.subject | Adult | en |
dc.subject | Antineoplastic Agents, Phytogenic/*administration & dosage | en |
dc.subject | Antineoplastic Combined Chemotherapy Protocols/administration & dosage | en |
dc.subject | Camptothecin/administration & dosage/adverse effects/*analogs & derivatives | en |
dc.subject | DNA Topoisomerases, Type I/antagonists & inhibitors | en |
dc.subject | Drug Administration Schedule | en |
dc.subject | Drug Resistance, Neoplasm | en |
dc.subject | Enzyme Inhibitors/administration & dosage | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasm Recurrence, Local/*drug therapy | en |
dc.subject | Organoplatinum Compounds/administration & dosage | en |
dc.subject | Ovarian Neoplasms/*drug therapy | en |
dc.title | Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 이효표 | - |
dc.contributor.AlternativeAuthor | 서상수 | - |
dc.contributor.AlternativeAuthor | 류상영 | - |
dc.contributor.AlternativeAuthor | 김종혁 | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.contributor.AlternativeAuthor | 박상윤 | - |
dc.contributor.AlternativeAuthor | 남주현 | - |
dc.contributor.AlternativeAuthor | 강순범 | - |
dc.contributor.AlternativeAuthor | 이경희 | - |
dc.contributor.AlternativeAuthor | 송용상 | - |
dc.identifier.doi | 10.1016/j.ygyno.2007.11.023 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.